InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register account icon
S&P 500
5,505.00
(
-0.71%
)
US TECH 100
19,000.00
(
-0.94%
)
Dow Jones
40,287.53
(
-0.93%
)
Brent Oil
81.88
(
0.00%
)
Bitcoin
66,786.38
(
0.10%
)
Post# of 3956
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

whytestocks

Send PM Follow Ignore
Followers 130
Posts 14996
Boards Moderated 1
Alias Born 06/04/2018

whytestocks

Re: None

Thursday, 12/12/2019 1:30:35 PM

Thursday, December 12, 2019 1:30:35 PM

Post# of 3956
News: $KLDO Kaleido Biosciences to Advance KB174 for Hepatic Encephalopathy Based on Positive Top-Line Results from a Clinical Study in Patients with Cirrhosis

- KB174 Exceeded the Targeted Reduction in a Biomarker of Microbiome Ammonia Production - KB174 Was Well Tolerated and No Clinically Significant or Serious Treatment-Related Adverse Events Were Observed LEXINGTON, Mass., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc ....

In case you are interested KLDO - Kaleido Biosciences to Advance KB174 for Hepatic Encephalopathy Based on Positive Top-Line Results from a Clinical Study in Patients with Cirrhosis
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up